Name | ML-9 |
Description | ML-9 suppresses MLCK, PKA, and PKC activity with Ki values of 4, 32, and 54 μM, respectively. ML-9 is a selective and effective inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK), and stromal interaction molecule 1 (STIM1) activity. ML-9 causes autophagy by stimulating autophagosome formation and inhibiting their degradation. |
In vitro | ML9 (50?μM; 1-4?hours) obviously enhances cleaved caspase-3 levels, reduced STIM1 protein levels by about 42%. ML9 (0-100?μM; 0-24?hours) has no reduction in cardiomyocyte viability, 50-100?μM obviously causes cell death [2]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 25 mg/mL (69.2 mM), Sonication is recommended.
|
Keywords | viability | STIM1 | Myosin | MLCK | ML-9 | ML9 | ML 9 | Inhibitor | inhibit | caspase | cardiomyocyte | CalciumChannel | Calcium Channel | AKT |
Inhibitors Related | Nisoldipine | Diltiazem hydrochloride | Levetiracetam | L-Ascorbic acid | L-Phenylalanine | Artemisinin | D-Menthol | Ethyl cinnamate | L-Ascorbic acid sodium salt | 1-Octanol | 2-Nitrobenzoic acid | 2,3-Butanediol |
Related Compound Libraries | Reprogramming Compound Library | Bioactive Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Antioxidant Compound Library | Inhibitor Library | Stem Cell Differentiation Compound Library | Anti-Prostate Cancer Compound Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max |